Hey if you didn’t know about it, maybe it is time to add XDATA as part of your market monitoring regimen, 14 days free trials are available here.
|A $71 million unregistered equity financing by Conkwest successfully drew to a close. The non-brokered investment round was placed among nine investors. The subscription started almost two weeks ago. A total of five unregistered securities offerings closed by the company raised an estimated $69.17 million.|
|Conkwest develops and commercializes a product pipeline for the treatment of cancers and viral infections. The company’s products are based on the proprietary cancer-killing cell line Neukoplast (also known as NK-92) – the only cell line that can be commercialized as a direct, scalable, off-the-shelf cancer-killing product. The company is backed by Dr. Patrick Soon-Shiong and Sorrento Therapeutics.|
|The company is headquartered in Cardiff-by-the-sea CA. Conkwest elected to keep its revenues undisclosed.
The executive team includes Barry J Simon, Patrick Soon-Shiong and Richard Gomberg.
The board of directors includes Hans Klingemann, Henry Ji, John C Thomas, John T Potts, Richard Kusserow, Robert Rosen and Steve Gorlin.The company has raised an estimated total of $140.17 million via private unregistered security offerings.
Amount offered: $71 million
Amount placed: $71 million
SEC filing: Source
First sale: 06-10-2015
Data as of: 06-22-2015